Avidity Set To File First Of Three Muscular Dystrophy Drugs In 2025

The company is moving quickly to bring its antibody oligonucleotide conjugates to patients in three separate muscular dystrophy diseases, causing unease for its rivals.

(Shutterstock)

Avidity Biosciences could be about to transform treatment of three muscular dystrophy diseases with first-in-class RNA-based therapies, the most advanced being on track for filing by the end of 2025.

The San Diego, CA-based firm is developing a new hybrid drug class called antibody oligonucleotide conjugates (AOCs), which use monoclonal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from J.P. Morgan

BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches

 
• By 

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.

Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

 
• By 

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.

Momentum In Women’s Health, But Big Obstacles Too

 

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

 
• By 

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

More from Therapy Areas

Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag

 

The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.

Wegovy’s Win In MASH Gives Novo A Much-Needed Edge Over Lilly

 
• By 

Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.

Leo Keeps On Profitable Path With Solid H1 Sales Growth

 
• By 

The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.